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Abstract. Cancer stem cells (CSCs) are a subpopulation of 
cancer cells responsible for tumor maintenance and relapse 
due to their ability to resist various anticancer effects. Owing 
to the resistance of CSCs to the effects of targeted therapy, an 
alternative strategy that targets post-translational glycosylation 
may be an improved approach to treat cancer as it disrupts 
multiple coordinated signaling that maintains the stemness 
of CSCs. Glucosamine acts as an anticancer agent possibly 
by inhibiting N-linked glycosylation. The aim of the present 
study was to investigate the effect of glucosamine on the stem-
ness of breast CSCs, which is regulated by signal transducer 
and activator of transcription 3 (STAT3) signaling. Human 
aldehyde dehydrogenase-positive (ALDH+) breast CSCs and 
MCF7 cells were treated with various concentrations (0.25, 
1 or 4 mM) of glucosamine for 24 h. Subsequently, cell 
viability was determined by performing a trypan blue exclu-
sion assay, pluripotency gene [ALDH 1 family member A1 
(ALDH1A1), octamer-binding transcription factor 4 (OCT‑4), 
and Krüppel-like factor 4 (KLF4)] expression was determined 
using the reverse transcription-quantitative polymerase chain 
reaction, and STAT3 and phosphorylated STAT3 (pSTAT3) 
levels were determined by performing western blot analysis. 
Furthermore, the number of mammosphere-forming units 
(MFUs) in ALDH+ breast CSCs and MCF7 cells was 
determined. It was determined that glucosamine treatment 
decreased the viability of ALDH+ breast CSCs. Glucosamine 
treatment also decreased the stemness of ALDH+ breast CSCs 
and MCF7 cells, as indicated by decreased ALDH1A1, OCT‑4 
and KLF4 expression level, and a decreased number of MFUs. 
This effect of glucosamine may be associated with a decreased 
pSTAT3/STAT3 ratio, indicating that glucosamine inhibited 
STAT3 activation; therefore, the results of the present study 
indicated that glucosamine treatment may be an improved 
approach to target the stemness of CSCs.
Introduction
Cancer stem cells (CSCs) are a subpopulation of cancer cells 
that exhibit self-renewal and pluripotency (1). These traits of 
CSCs are associated with their ability to divide asymmetrically 
and produce an increased proportion of differentiated progeny 
cells, respectively, which enables them to seed tumors (2). 
Furthermore, CSCs possess distinctive characteristics, 
including high tumor-initiating potential, resistance to thera-
pies and tumor recurrence (3). The stemness of a population 
of cancer cells corresponds to the proportion and tumorige-
nicity of CSCs present in this population (1). Furthermore, 
stemness is associated with distinct changes in pluripotency 
gene expression (3). The expression of transcription factors, 
including octamer-binding transcription factor 4 (OCT-4), 
sex-determining region Y-related high mobility group box 
gene 2 (SOX2) and Krüppel-like factor 4 (KLF4), is increased 
in CSCs, compared with non-CSCs, and confers the ability of 
self-renewal on CSCs (4-6).
CSCs have been successfully isolated from various tumor 
types, with breast CSCs being the first solid tumor‑derived 
CSCs (7). Expression of cell-surface markers, including 
CD24lowCD44high, may be used to identify breast CSCs (8). 
Alternatively, breast CSCs may be identified on the basis 
of aldehyde dehydrogenase (ALDH) activity (9). High 
pluripotency gene expression has also been observed in 
CD24lowCD44high and ALDH+ CSCs (10).
In breast CSCs, pluripotency gene expression is regulated 
by complex signal transduction pathways, including the signal 
transducer and activator of transcription 3 (STAT3) signaling 
pathway (11,12). Previous studies have identified that the 
transcription factor STAT3 serves a significant function in 
the expression of pluripotency genes, including OCT‑4, SOX2, 
KLF4 and ALDH 1 family member A1 (ALDH1A1) (13,14). 
Phosphorylation of STAT3 at Tyr705 induces its activation and 
enables it to act as a potent activator of pluripotency gene 
transcription. Results of in vitro and in vivo studies have 
demonstrated that an increased level of phosphorylated STAT3 
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(pSTAT3) is associated with mammosphere-forming capacity, 
self-renewal, increased invasiveness, tumor-generating 
capacity and metastatic potential, and that targeted STAT3 
inhibition suppresses relapse and metastasis in an animal 
model (15).
Post‑translational modification (PTM) is an important step 
in cellular protein maturation and involves the chemical modi-
fication of the protein structure, resulting in the generation 
of various modified forms of a protein. Global inhibition of 
protein N-glycosylation inhibits the Janus kinase (JAK)-STAT 
signaling pathway and other signaling pathways in cancer 
cells (16). Owing to targeted therapy being resisted by CSCs, 
PTM inhibition is preferred over targeted therapy for cancer 
treatment; however, PTM inhibition is undermined by the 
problem of toxicity, as it induces considerable damage by 
affecting multiple signaling pathways. A previous study iden-
tified that the toxicity was associated with tunicamycin, an 
N-glycosylation inhibitor (17).
Glucosamine is a naturally occurring amino monosaccha-
ride that is primarily located in connective and cartilage tissues, 
where it serves as an essential component for maintaining 
flexibility and elasticity; therefore, glucosamine is frequently 
used for treating osteoarthritis in humans (18). Glucosamine 
has been indicated to be a candidate N-glycosylation inhibitor 
due to its anticancer activity (16,18). Chesnokov et al (16) 
indicated that glucosamine decreased the N-linked glyco-
sylation of gp130, a highly glycosylated interleukin 6 (IL-6) 
receptor subunit, resulting in the inhibition of the IL-6-STAT3 
signaling pathway. Currently, to the best of our knowledge, it 
has not been examined whether glucosamine is able to modify 
CSC stemness; therefore, in the present study, the effect of 
glucosamine on the stemness of ALDH+ breast CSCs was 
investigated.
Materials and methods
Reagents. D-glucosamine hydrochloride was purchased 
from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). 
Dulbecco's  modi f ied Eagle's  medium /Ham's F12 
(DMEM-F12) and high-glucose DMEM were purchased 
from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, 
USA). Penicillin/streptomycin/amphotericin B mixture was 
purchased from Lonza Group, Ltd. (Basel, Switzerland). 
An ALDEFLUOR™ kit was purchased from Stemcell 
Technologies, Inc. (Vancouver, BC, Canada). Recombinant 
human fibroblast growth factor (cat. no. 064‑05381) was 
purchased from Wako Chemicals USA, Inc. (Richmond, 
VA, USA). The antibodies used in the present study were 
as follows: Mouse anti-human STAT3 antibody (124H6; 
cat. no. 9139; Cell Signaling Technology, Inc., Danvers, 
MA, USA); mouse anti-human pSTAT3 (Tyr705) antibody 
(3E2; cat. no. 9138; Cell Signaling Technology, Inc.); 
mouse anti-human GAPDH antibody (cat. no. sc-47724; 
Santa Cruz Biotechnology Inc., Dallas, TX, USA); and 
horseradish peroxidase (HRP)-conjugated goat anti-mouse 
immunoglobulin G (IgG; cat. no. sc-2005; Santa Cruz 
Biotechnology, Inc.).
Cell culture and glucosamine treatment. ALDH+ breast CSCs 
isolated from pleural effusion of a patient with metastatic 
breast cancer were provided by Professor Osamu Ohneda 
(Laboratory of Regenerative Medicine and Stem Cell Biology, 
Graduate School of Comprehensive Human Sciences, 
University of Tsukuba, Tsukuba, Japan). Additionally, 
these cells have been established as a cell line, as described 
previously (19,20). To retain their stemness, ALDH+ breast 
CSCs were cultured in serum-free DMEM-F12 supplemented 
with 1% penicillin/streptomycin/amphotericin B at 37˚C in an 
atmosphere containing 5% CO2, as described previously (21,22). 
Our preliminary experiments performed using the ALDH+ 
breast CSCs confirmed that treatment with 10% fetal bovine 
serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) induced 
differentiation of these CSCs, with notable changes in their 
morphology from floating and sphere‑like cells to attached 
and epithelial-like cells (data not shown).
Human adherent epithelial adenocarcinoma cell line 
MCF7 was purchased from the American Type Culture 
Collection (Manassas, VA, USA). These cells were cultured 
in high-glucose DMEM supplemented with 10% (v/v) FBS 
and 1% penicillin/streptomycin/amphotericin B at 37˚C in an 
atmosphere containing 5% CO2.
ALDH+ breast CSCs and MCF7 cells were seeded in 
a 6-well plate (1x105 cells/well) and were cultured under 
aforementioned conditions. After 24 h, DMEM-F12 was 
replaced with serum-free medium containing D-glucosamine 
hydrochloride. The concentrations of D-glucosamine used for 
ALDH+ breast CSCs were 0.25, 1, 4, 10 or 16 mM, whereas 
for MCF7 cells the concentrations used were 0.25, 1 or 4 mM. 
The control was ALDH+ breast CSCs or MCF7 cells without 
D‑glucosamine treatment. Following 24 h treatment at 37˚C, 
the cells were harvested for further analysis.
Cell viability assay. Cell viability was determined by 
performing a trypan blue exclusion assay. Cell suspension was 
stained with 0.4% trypan blue solution (1:1 mixture) and was 
allowed to stand for 2 min at room temperature. Viable and 
dead cells were counted using a Luna™ automated cell counter 
(Logos Biosystems, Anyang, Gyeonggi, Korea). Relative 
viability was calculated using the following formula: Viability 
(%)=(number of viable cells/number of total cells) x100.
Mammosphere formation assay. Breast CSCs were seeded 
at a density of 100 cells/well in an ultra-low attachment 
96-well plate (Corning Incorporated, New York, NY, USA) 
and grown in DMEM-F12 supplemented with 0, 0.25, 1, 4, 10 
or 16 mM glucosamine at 37˚C in an atmosphere containing 
5% CO2. Formation of mammospheres from the breast CSCs 
was determined after 3 days. MCF7 cells were seeded at a 
density of 200 cells/well in an ultra-low attachment 96-well 
plate and grown in high-glucose DMEM supplemented with 
20 ng/ml basic fibroblast growth factor at 37˚C in an atmo-
sphere containing 5% CO2. Formation of mammospheres from 
MCF7 cells was determined after 7 days.
The formation of mammosphere was observed under 
inverted microscope at x100 magnification (model no. IM‑3; 
OPTIKA Srl, Ponteranica, Italy). Spheres ≥60 µm in diameter 
were counted as mammosphere-forming units (MFUs) (23) 
using OPTIKA Srl software (version 2.7; OPTIKA Srl). 
Diameters of irregularly shaped spheres were determined 
using the shortest diameter.
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RNA extraction and reverse transcription‑quantitative poly‑
merase chain reaction (RT‑qPCR). For performing RT-qPCR, 
total RNA was extracted from the cells using the TriPure Isolation 
Reagent (Roche Diagnostics, Basel, Switzerland), according to 
the manufacturer's protocol. RNA concentration was measured 
spectrophotometrically by using a Varioskan Flash Multimode 
Reader (Thermo Fisher Scientific, Inc.) and the isolated RNA 
was stored at ‑80˚C. RT‑qPCR was performed using a KAPA™ 
SYBR® FAST One-Step qRT-PCR kit (Kapa Biosystems, Inc., 
Wilmington, MA, USA) and Exicycler™ 96 thermal block 
(Bioneer Corporation, Daejeon, Korea). PCR was performed 
using the following primers: OCT‑4 forward, 5'-GAG GAG 
TCC CAG GAC ATC AAA-3' and reverse, 5'-AGC TTC CTC 
CAC CCA CTT CT-3'; ALDH1A1 forward, 5'-GGA GGA AAC 
CCT GCC TCT TTT-3' and reverse, 5'-TTG GAA GAT AGG 
GCC TGC AC-3'; KLF4 forward, 5'-CCG CTC CAT TAC CAA 
GAG-3' and reverse, 5'-TTT CTC ACC TGT GTG GGT TC-3'; 
and 18S rRNA gene forward, 5'-AAA CGG CTA CCA CAT CCA 
AG-3' and reverse, 5'-CCT CCA ATG GAT CCT CGT TA-3'. The 
conditions for PCR are as follows: Initial denaturation at 42˚C 
for 5 min and 95˚C for 5 min; followed by 40 cycles of dena-
turation at 95˚C for 30 sec, annealing at optimal temperature 
(57˚C, 59˚C, 55˚C and 60˚C for OCT‑4, ALDH1A1, KLF4, 
and 18S rRNA, respectively) for 20 sec and extension at 72˚C 
for 20 sec. Amplicon levels of the target genes are expressed 
relative to those of the 18S rRNA gene, which was used as an 
internal control, using the ∆∆Cq method (24).
Western blot analysis. Following treatment with glucosamine, 
the cells were washed twice with PBS and were lysed for 
10 min in radioimmunoprecipitation assay buffer (Santa 
Cruz Biotechnology, Inc.) containing an anti-protease 
mixture. Protein concentration was determined using the 
Bradford method (25). Protein fractions were suspended in a 
Laemmli sample buffer (Bio-Rad Laboratories, Inc.) and were 
denatured at 100˚C for 5 min. Total protein (20 µg/lane) were 
separated by SDS-PAGE (12% gel) and were transferred onto 
nitrocellulose membranes (Bio-Rad Laboratories, Inc.). The 
membranes were blocked by incubation with 5% bovine serum 
albumin (Nacalai Tesque, Inc., Kyoto, Japan) in Tris-buffered 
saline containing 0.1% Tween-20 for 1 h at room temperature 
and were incubated overnight at 4˚C with mouse anti‑human 
monoclonal antibodies against STAT3 (1:2,000 dilution), 
pSTAT3 (1:1,000 dilution) and GAPDH (1:200 dilution). The 
blots were visualized using HRP-conjugated anti-mouse IgG 
(1:2,000 dilution) and enhanced chemiluminescence reagent 
(cat. no. ab133406; Abcam, Cambridge, UK). Intensities 
of bands representing pSTAT3 and STAT3 expression 
levels were calculated using ImageJ software (Version 
1.50i; National Institutes of Health, Bethesda, MD, USA), 
and the pSTAT3/STAT3 ratio was calculated using the 
formula: pSTAT3/STAT3 ratio=(pSTAT3 intensity/GAPDH 
intensity)/(STAT3 intensity/GAPDH intensity).
Statistical analysis. All results are expressed as mean ± standard 
deviation of at least three independent experiments. Statistical 
analysis was performed using SPSS 20.0 software (IBM 
Corp., Armonk, NY, USA). Statistical differences among the 
groups were determined using one-way analysis of variance 
and Duncan post hoc test. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Glucosamine decreases ALDH+ CSC viability. The effects of 
various concentrations of glucosamine on the viability of ALDH+ 
breast CSCs and MCF7 cells was determined using a trypan 
blue exclusion assay. Glucosamine treatment (0.25, 1, 4, 10 or 
16 mM) gradually decreased ALDH+ breast CSC viability in a 
dose-dependent manner. Treatment with glucosamine in ALDH+ 
breast CSCs for different durations demonstrated that the shorter 
duration (24 h) of treatment resulted in a greater decrease in cell 
viability, compared with the longer duration (48 h) of treatment 
(Fig. 1); however, MCF7 cell viability did not significantly alter 
following glucosamine treatment (0.25, 1 or 4 mM) (Fig. 1).
Glucosamine downregulates the expression of stemness 
genes in ALDH+ breast CSCs and MCF7 cells. ALDH1A1 is 
a detoxifying enzyme in the aldehyde metabolic pathway (9). 
Furthermore, ALDH1A1 has been proposed as a marker 
Figure 1. Viability of (A) aldehyde dehydrogenase-positive breast CSCs and (B) MCF7 cells. The CSCs were treated with 0.25, 1, 4, 10 or 16 mM glucosamine, 
whereas MCF7 cells were treated with 0.25, 1 or 4 mM glucosamine. Cell viability was determined by performing a trypan blue exclusion assay. Data are 
presented as the mean ± standard deviation of at least three independent experiments. *P<0.05 vs. corresponding control cells. CSCs, cancer stem cells.
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for identifying and isolating CSCs from various cancer cells, 
including breast cancer cells (9). ALDH1A1 expression was 
increased 1.8-fold in untreated ALDH+ breast CSCs, compared 
with in MCF7 cells (Fig. 2A). Compared with the control, 
treatment with 4 mM glucosamine significantly downregu-
lated ALDH1A1 expression in ALDH+ breast CSCs (0.7-fold; 
P<0.05) and MCF7 cells (0.49-fold; P<0.01) (Fig. 2A). OCT-4 
and KLF4 are transcription factors expressed in embryonic and 
adult human stem cells. They are termed Yamanaka factors due 
to their major functions in induced pluripotent stem cells (26). 
OCT‑4 and KLF4 expression was increased 1.8- and 2-fold, 
respectively, in untreated CSCs, compared with untreated 
MCF7 cells (Fig. 2B and C). Glucosamine treatment (4 mM) 
significantly downregulated OCT‑4 (0.46-fold; P<0.01) and 
KLF4 expression (0.42-fold; P<0.01) in ALDH+ breast CSCs, 
compared with their respective control. The downregulation 
of OCT‑4 expression following glucosamine treatment demon-
strated a similar pattern in ALDH+ breast CSCs and MCF7 
cells (Fig. 2B); however, KLF4 expression was upregulated in 
MCF7 cells (Fig. 2C), compared with the control.
Glucosamine decreases mammosphere formation in ALDH+ 
breast CSCs and MCF7 cells. To examine whether glucosamine 
treatment affected the self-renewal capacity of CSCs, an in vitro 
mammosphere formation assay was performed. Results of our 
preliminary experiments demonstrated that mammospheres 
of ≥60 µm in diameter were formed in ALDH+ breast CSCs 
on the third day, whereas in MCF7 cells these formed on 
the seventh day following seeding, indicating increased 
tumorigenicity of ALDH+ breast CSCs, compared with MCF7 
cells. Furthermore, this result demonstrated that CSCs were 
more enriched in ALDH+ breast cancer cells, compared 
with MCF7 cells. The number of mammospheres formed 
by untreated ALDH+ breast CSCs was markedly increased 
(5.02-fold), compared with MCF7 cells (Fig. 3). Treatment 
with 4 mM glucosamine significantly decreased the MFUs in 
ALDH+ breast CSCs and MCF7 cells. Notably, the decrease 
in MFUs in glucosamine-treated ALDH+ breast CSCs was 
significantly increased, compared with glucosamine‑treated 
MCF7 cells (Fig. 3).
Glucosamine suppresses STAT3 signaling in ALDH+ breast 
CSCs and MCF7 cells. Subsequently, the activation of the 
STAT3 pathway, a key signaling pathway, was examined in 
ALDH+ breast CSCs. STAT3 is activated through phosphory-
lation, and activated STAT3 induces the expression of target 
genes, including OCT‑4, SOX2, KLF4 and ALDH1A1 (13,14). 
STAT3 and pSTAT3 levels were determined by western 
blot analysis. Activation of the STAT3 signaling pathway 
was determined by calculating the pSTAT3/STAT3 ratio. 
Glucosamine treatment inhibited STAT3 phosphorylation in 
ALDH+ breast CSCs and MCF7 cells (Fig. 4); however, 4 mM 
glucosamine-induced inhibition of STAT3 phosphorylation in 
ALDH+ breast CSCs was less significant (P<0.05), compared 
with that in MCF7 cells (P<0.01).
Discussion
Eradication of cancer cells following therapy has always been 
difficult due to their resistance to the anticancer effects of the 
therapy. In chemotherapy, cancer cells resist eradication by 
pumping out drugs or by preventing the induction of apoptotic 
cascades (27). In targeted therapy, cancer cells resist eradica-
tion by compensating for the decreased or missing activity of 
a particular protein by activating other pathways, including 
IL-6/STAT3 and Notch3, to sustain their oncogenic state 
and/or stemness (28).
In the present study, the decision to inhibit PTM as an 
approach for non-targeted anticancer therapy was primarily 
based on tumor heterogeneity, which is one of the causes 
of the failure of cancer treatment. Theoretically, a highly 
heterogeneous population of cancer cells can survive targeted 
therapy due to them having a high possibility of containing a 
resistant clone (29). This assumption was confirmed by reports 
on the enrichment of CSCs following chemotherapy (30). 
Residual CSCs adopt numerous mechanisms to withstand 
various therapies, including targeted therapy (27); therefore, 
to prevent any form of ‘bounce back’ following targeted 
Figure 2. Expression of stemness genes in ALDH+ breast CSCs and MCF7 
cells following glucosamine treatment. The cells were treated with various 
concentrations of glucosamine for 24 h, as indicated. Total RNA was 
isolated, reverse-transcribed and analyzed using the quantitative polymerase 
chain reaction for determining the expression of (A) ALDH1A1, (B) OCT‑4 
and (C) KLF4. Data are presented as the mean ± standard deviation of at 
least three independent experiments. *P<0.05 and **P<0.01 vs. corresponding 
control cells. ALDH+, aldehyde dehydrogenase-positive; ALDH1A1, aldehyde 
dehydrogenase 1 family member A1; OCT‑4, octamer-binding transcription 
factor 4; KLF4, Krüppel-like factor 4; CSCs, cancer stem cells.
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therapy, it was considered that a reasonable approach was to 
target the most pathways possible without endangering normal 
cells. As reported previously, CSCs have difficulty rewiring 
important pathways due to PTM inhibition affecting multiple 
pathways (16). Furthermore, due to drug efflux transporters, 
including multidrug resistance protein 1 (MDR1), requiring 
appropriate glycosylation, cancer cells may not be able to 
resist the effects of chemotherapy following PTM inhibi-
tion (31); therefore, it was indicated that PTM inhibition is 
preferable to targeted therapy for eradicating CSCs.
As described previously, toxicity is the primary drawback 
of the global inhibition of N-glycosylation. This indicates the 
requirement for developing a strategy, in which cancer cells intake 
increased amount of PTM inhibitor, compared with normal cells. 
A possible way to address this issue is to utilize the concept of 
cancer cell metabolism, known as the Warburg effect. To survive 
under relatively hypoxic conditions, cancer cells adjust their 
metabolism to a glycolytic state, thus increasing lactate produc-
tion; therefore, cancer cells exhibit high glucose uptake (32). 
Glucosamine was used to inhibit the protein N-glycosylation in 
the present study due to its structure mimicking the structure of 
glucose and it exhibiting low toxicity (16,33).
The anticancer activity of glucosamine has been known 
for >50 years; however, the mechanism underlying the 
anticancer activity of glucosamine remains unclear (34). 
A number of mechanisms, including autophagy induction, 
proteasomal activity inhibition, cell cycle arrest, nuclear 
factor-κB inhibition and N-glycosylation inhibition, have 
been proposed (18). Glucosamine is indicated to inhibit the 
activity of JAK/STAT signaling proteins, including STAT3, 
by inhibiting the N-glycosylation of gp130, a subunit of 
the IL-6 receptor complex (16); however, to the best of our 
knowledge, it has not been examined whether glucosamine 
affects stemness. In the present study, it was observed 
that glucosamine decreased ALDH1A1, OCT‑4 and KLF4 
expression and the mammosphere-forming ability of ALDH+ 
breast CSCs and MCF7 cells, indicating that glucosamine 
decreased the stemness of these cells. These changes are 
consistent with the decreased pSTAT3/STAT3 ratio in these 
cells. On the basis of results of previous studies (13,15), 
we hypothesized that the downregulation of stemness gene 
expression in ALDH+ breast CSCs and MCF7 cells following 
glucosamine treatment may be a functional consequence of 
STAT3 inactivation.
Figure 3. Effects of glucosamine on mammosphere formation by ALDH+ breast CSCs and MCF7 cells. (A) Representative photographs of aldehyde dehydro-
genase‑positive breast CSC and MCF7 cell mammospheres were acquired on the third and seventh day, respectively, following seeding. Scale bar, 100 µm. 
(B) The number of mammospheres was counted under an inverted microscope, and MFUs were calculated. Spheres ≥60 µm in diameter were counted as a 
single MFU. Diameters of irregularly shaped spheres were determined using the shortest diameter. Data are presented as the mean ± standard deviation of at 
least three independent experiments. *P<0.05 and **P<0.01 vs. control cells. CSCs, cancer stem cells; MFUs, mammosphere-forming units.
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The results from the western blot analysis confirmed that 
glucosamine significantly inhibited STAT3 phosphoryla-
tion of CSCs and MCF7 cells to a similar degree. The less 
significant inhibitory effect of 4 mM glucosamine in ALDH+ 
breast cancer cells may be due to the increased abundance of 
CSCs in ALDH+ breast cancer cells, compared with MCF7 
cells, which exerted a density-dependent effect on chemore-
sistance, as indicated by He et al (35). CSCs may also attempt 
to maintain their stemness by activating other pathways 
that contribute to STAT3 activation, including overactiva-
tion of the G-protein-coupled receptor signaling pathway or 
overexpression of gp130 (36).
Furthermore, it was observed that the reduction of the 
pSTAT3/STAT3 ratio was consistent with the decrease in the 
expression of stemness genes OCT‑4 and ALDH1A1. These 
results confirmed the results of previous studies that reported 
that OCT‑4 and ALDH1A1 were regulated by the transcription 
factor STAT3 (13,14); however, a STAT3 inhibitor was not 
used in the present experiments, which is a limitation of the 
present study. Lin et al (13) demonstrated that inhibition of 
STAT3 phosphorylation using Stattic and LLL12 decreased 
the tumorigenicity and viability of ALDH+ breast CSCs; there-
fore, we hypothesized that the downregulation of stemness 
gene expression observed in the present study was a functional 
consequence of STAT3 inactivation.
Consistent with previous studies (16,37) involving various 
prostate cancer and non-small cell lung cancer cells, the results 
of the present study demonstrated that treatment with ≥4 mM 
glucosamine significantly decreased the viability of human 
ALDH+ breast CSCs. This confirmed the requirement of a high 
glucosamine concentration for in vitro study. In the present 
study, glucosamine treatment in a xenograft mice model 
was not investigated owing to circumstances and limitations 
in available animal laboratory facilities. In order to reach 
an effective concentration in vivo, it is considered that there 
will be difficulties. In the study reported by Song et al (37), 
using a xenograft mouse lung tumor model, glucosamine 
was required to be introduced at a concentration as high as 
500 mg/kg body weight in order to achieve a significant benefit 
of glucosamine. Furthermore, Weimer et al (38) reported 
that the plasma level of glucosamine in a mouse model may 
be increased up to ~2 µM. Notably, it was observed that the 
effects of glucosamine on ALDH+ breast CSC viability are 
increased after 24 h of treatment, compared with after 48 h; 
however, the glucosamine treatments for longer durations 
were not performed in the present study due to MCF7 cells 
not surviving in serum‑free treatment medium for ≥48 h. If 
the effect of stemness suppression is only short-term, it may 
indicate that glucosamine treatment should be repeated as 
necessary to replenish the effect.
In contrast with ALDH+ breast CSCs, a significant 
effect of glucosamine on the viability of MCF7 cells was 
not observed. Distinct metabolic pathways in CSCs and 
non-CSCs may be responsible for different responses to 
glucosamine treatment. For example, CD44+CD117+ ovarian 
CSCs exhibit increased glucose uptake, compared with 
CD44+CD117- ovarian non-CSCs (39). Additionally, the 
differential effects of glucosamine on the viability of ALDH+ 
breast CSCs and MCF7 cells may depend on the density of 
CSCs in ALDH+ breast cancer cells, compared with MCF7 
cells, due to STAT3 inactivation as aforementioned. Owing to 
the notably lower density of CSCs in MCF7 cells, compared 
with ALDH+ breast cancer cells, we hypothesized that 
STAT3 inactivation following glucosamine treatment may 
be a mediator of the antiproliferative effect of glucosamine, 
which specifically targets CSCs.
Figure 4. Glucosamine treatment decreased STAT3 phosphorylation in aldehyde dehydrogenase-positive breast CSCs and MCF7 cells. (A) STAT3 and pSTAT3 
levels were examined by performing western blot analysis, with GAPDH as a loading control. (B) The pSTAT3/STAT3 ratio was calculated based on densi-
tometric quantification of the blots compared with GAPDH. Data are presented as the mean ± standard deviation of at least three independent experiments. 
*P<0.05 and **P<0.01 vs. control cells. STAT3, signal transducer and activator of transcription 3; pSTAT3, phosphorylated STAT3; CSCs, cancer stem cells.
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Although it was determined that glucosamine treat-
ment significantly decreased CSC viability, the extent of the 
decrease in cell viability was less than that induced by Stattic- 
and LLL12-targeted therapy in ALDH+ breast CSCs (13,15); 
therefore, we hypothesized that glucosamine treatment may be 
improved when applied as an adjuvant therapy. There are two 
previous studies that identified that an N‑glycosylation inhib-
itor acts as a chemosensitizer by affecting transporter proteins 
involved in multidrug resistance, including MDR1 (31). 
Furthermore, the global inhibition of PTM may affect the CSC 
niche (40), thus overcoming problems associated with CSC 
targeting, particularly problems associated with plasticity and 
epithelial-mesenchymal transition (41).
In conclusion, to the best of our knowledge, the present 
study is the first to demonstrate that glucosamine affected the 
stemness of human ALDH+ breast CSCs, thus decreasing their 
viability. This effect of glucosamine may be associated with 
the inhibition of STAT3 phosphorylation; however, further 
investigations with xenograft animal models are required to 
verify the effects of glucosamine observed in the present study.
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